Journal
JOURNAL OF IMMUNOLOGY
Volume 207, Issue 7, Pages 1755-1762Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2100349
Keywords
-
Categories
Funding
- Canon Medical Systems Corporation
- MEXT, Japan Society for the Promotion of Science
Ask authors/readers for more resources
Screening of over 1800 anti-mCRP mAb clones identified 3C as a clone recognizing the monomeric form of CRP, which showed therapeutic potential against rheumatoid arthritis and lupus nephritis in mouse models.
Conformation-specific Ags are ideal targets for mAb-based immunotherapy. Here, we demonstrate that the monomeric form of C-reactive protein (mCRP) is a specific therapeutic target for arthritis and nephritis in a murine model. Screening of >1800 antimCRP mAb clones identified 3C as a clone recognizing the monomeric, but not polymeric, form of CRP. The anti-mCRP mAb suppressed leukocyte infiltration in thioglycollate-induced peritonitis, attenuated rheumatoid arthritis symptoms in collagen Ab-induced arthritis model mice, and attenuated lupus nephritis symptoms in MRL/Mp-lpr/lpr lupus-prone model mice. These data suggest that the anti-mCRP mAb 3C has therapeutic potential against rheumatoid arthritis and lupus nephritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available